A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The main purpose of this research study is to see if the study drug, named CP-724,714, can
help in the treatment of certain breast cancers that have spread to other locations in the
body. Other goals of this study are to measure how long it may take for the cancer to get
worse (progress), to see if there are any side effects from the study drug, to check the
amount of study drug in the blood at different times, and to check to see if there is any
relationship between certain blood tests and how patients may respond to the study drug.
About 25 subjects at 4 sites (hospitals and clinics) in Bulgaria and Russia will be involved
in the trial. Participation in this study can last up to 48 weeks, depending on the
participant's toleration of the study drug and the response of her tumor(s) to the study
drug. All participants will receive CP-724,714, at a daily dose of 250 mg (4 pills) every 12
hours.